% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Unglaub:293338,
      author       = {J. M. Unglaub and R. Schlenk$^*$ and J. M. Middeke and S.
                      W. Krause and S. Kraus and H. Einsele and M. Kramer and S.
                      Zukunft and J. Kauer and S. Renders and E. Katelari and C.
                      Schliemann and C. Pabst and T. Luft and P. Dreger and C.
                      Röllig and M. Bornhäuser and C. Müller-Tidow and T.
                      Sauer},
      title        = {{V}enetoclax-based salvage therapy as bridge-to-transplant
                      is feasible and effective in patients with
                      relapsed/refractory {AML}.},
      journal      = {Blood advances},
      volume       = {9},
      number       = {2},
      issn         = {2473-9529},
      address      = {Washington, DC},
      publisher    = {American Society of Hematology},
      reportid     = {DKFZ-2024-01886},
      pages        = {375-385},
      year         = {2025},
      note         = {2025 Jan 28;9(2):375-385},
      abstract     = {The BCL2-inhibitor Venetoclax (VEN) in combination with
                      hypomethylating agents (HMA) has been approved for
                      first-line treatment of acute myeloid leukemai (AML)
                      patients ineligible for intensive treatment. Emerging Data
                      suggest that VEN containing treatment strategies may also be
                      effective in relapsed/refractory (R/R) AML, however,
                      comparative studies with conventional treatment strategies
                      for medically fit patients as a bridge-to transplant
                      strategy are limited. Using propensity score matching (PSM)
                      analysis, we compared 37 R/R AML patients, who received
                      VEN-based salvage therapy as bridge to allogeneic
                      hematopoietic cell transplantation (allo-HCT) with 90
                      patients from the German Study Alliance Leukemia (SAL) AML
                      registry, who were treated with non-VEN-containing salvage
                      therapy according to their treating physician's choice (TPC)
                      including intensive and non-intensive protocols. The overall
                      response rate (ORR=CR+CRi) among all VEN patients was
                      significantly higher compared to the TPC control cohort
                      $(62\%$ vs. $42\%;$ p=0.049). Overall, $73\%$ of VEN-treated
                      patients vs. $63\%$ of TPC patients were successfully
                      bridged to allo-HCT (p =0.41). After a median follow-up of
                      34.3 months for the VEN cohort and 21.0 months for the TPC
                      cohort, the median overall-survival (OS) was 15.8 months
                      $(95\%-CI,$ 10.6-NE) and 10.5 months $(95\%-CI,$ 6.8-19.6)
                      (p=0.15), respectively. PSM revealed a trend towards
                      improved OS for VEN patients (HR 0.70; $95\%-CI,$ 0.41-1.22;
                      p=0.20). Median event free survival (EFS) was significantly
                      longer in the VEN cohort (8.0 months) compared to the TPC
                      cohort (3.7 months) (p=0.006). In summary, our data suggests
                      that VEN-based salvage therapy is a safe and effective
                      bridge to allo-HCT for this difficult-to-treat AML patient
                      population.},
      cin          = {W010},
      ddc          = {610},
      cid          = {I:(DE-He78)W010-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39293081},
      doi          = {10.1182/bloodadvances.2024013086},
      url          = {https://inrepo02.dkfz.de/record/293338},
}